Patents Assigned to OPKO CuRNA, LLC
  • TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)
    Publication number: 20120252869
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Application
    Filed: July 23, 2010
    Publication date: October 4, 2012
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE
    Publication number: 20120171170
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Collagen gene, in particular, by targeting natural antisense polynucleotides of a Collagen gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Collagen genes.
    Type: Application
    Filed: June 16, 2010
    Publication date: July 5, 2012
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF INSULIN GENE (INS) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN INSULIN GENE (INS)
    Publication number: 20120149759
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Insulin gene (INS), in particular, by targeting natural antisense polynucleotides of an Insulin gene (INS). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Insulin Gene (INS).
    Type: Application
    Filed: August 5, 2010
    Publication date: June 14, 2012
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF 'IQ MOTIF CONTAINING GTPASE ACTIVATING PROTEIN' (IQGAP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IQGAP
    Publication number: 20120142610
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘IQ motif containing GTPase activating protein’ (IQGAP), in particular, by targeting natural antisense polynucleotides of ‘IQ motif containing GTPase activating protein’ (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IQGAP.
    Type: Application
    Filed: August 25, 2010
    Publication date: June 7, 2012
    Applicant: OPKO CURNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • TREATMENT OF ADIPONECTIN (ADIPOQ) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN ADIPONECTIN (ADIPOQ)
    Publication number: 20120129917
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Adiponectin (ADIPOQ), in particular, by targeting natural antisense polynucleotides of an Adiponectin (ADIPOQ). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Adiponectins (ADIPOQ)s.
    Type: Application
    Filed: August 11, 2010
    Publication date: May 24, 2012
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TNFR2
    Publication number: 20120094934
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TNFR2.
    Type: Application
    Filed: June 24, 2010
    Publication date: April 19, 2012
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sheman
  • TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) AND INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
    Publication number: 20120095079
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2) polynucleotides, in particular, by targeting natural antisense polynucleotides of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TFE3 and/or IRK.
    Type: Application
    Filed: May 21, 2010
    Publication date: April 19, 2012
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF ANTIVIRAL GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN ANTIVIRAL GENE
    Publication number: 20120088817
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Antiviral gene, in particular, by targeting natural antisense polynucleotides of an Antiviral gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Antiviral genes.
    Type: Application
    Filed: May 28, 2010
    Publication date: April 12, 2012
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
    Patent number: 8153606
    Abstract: Oligonucleotide compounds modulate expression and/or function of an apolipoprotein (ApoA1) polynucleotides and encoded products thereof. Methods for treating diseases associated with apolipoprotein-A1 (ApoA1) comprise administering one or more Oligonucleotide compounds designed to inhibit the Apo-A1 natural antisense transcript to patients.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: April 10, 2012
    Assignee: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova
  • TREATMENT OF REPROGRAMMING FACTOR RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A REPROGRAMMING FACTOR
    Publication number: 20120064048
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors.
    Type: Application
    Filed: May 18, 2010
    Publication date: March 15, 2012
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF DYSTROPHIN FAMILY RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO DMD FAMILY
    Publication number: 20120046345
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of Dystrophin family. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DMD family.
    Type: Application
    Filed: May 7, 2010
    Publication date: February 23, 2012
    Applicant: OPKO CURNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1
    Publication number: 20110319317
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of SIRT 1.
    Type: Application
    Filed: March 3, 2010
    Publication date: December 29, 2011
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
  • TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF
    Publication number: 20110319475
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of BDNF.
    Type: Application
    Filed: February 12, 2010
    Publication date: December 29, 2011
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • TREATMENT OF TUMOR SUPPRESSOR GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO THE GENE
    Publication number: 20110294870
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Tumor Suppressor genes.
    Type: Application
    Filed: December 3, 2009
    Publication date: December 1, 2011
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO VEGF
    Publication number: 20110237650
    Abstract: Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.
    Type: Application
    Filed: December 2, 2009
    Publication date: September 29, 2011
    Applicant: OPKO CURNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN 1
    Publication number: 20110237649
    Abstract: Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucleotide compounds designed to inhibit the SIRT1 natural antisense transcript to patients.
    Type: Application
    Filed: December 2, 2009
    Publication date: September 29, 2011
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
  • TREATMENT OF ERYTHROPOIETIN (EPO) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO EPO
    Publication number: 20110237651
    Abstract: Oligonucleotide compounds modulate expression and/or function of Erythropoietin (EPO) polynucleotides and encoded products thereof. Methods for treating diseases associated with Erythropoietin (EPO) comprise administering one or more oligonucleotide compounds designed to inhibit the EPO natural antisense transcript to patients.
    Type: Application
    Filed: December 3, 2009
    Publication date: September 29, 2011
    Applicant: OPKO CuRNA, LLC
    Inventors: Joseph Collard, Olga Khorkova Sherman